{"id":195242,"title":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-19","captureTimestamp":"2025-04-19T08:14:28.053000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false","snippet":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement…","rawSnapshotUrl":"/api/snapshots/raw/195242","browseUrl":"https://replay.healtharchive.ca/job-1/20250419081428/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false#ha_snapshot=195242","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}